Efficacy and safety of vorapaxar in patients with prior ischemic stroke.
about
Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarctionAdjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxarUnmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxarPharmacokinetic drug evaluation of vorapaxar for secondary prevention after acute coronary syndrome.Differential signaling by protease-activated receptors: implications for therapeutic targeting.Efficacy and safety of vorapaxar as approved for clinical use in the United StatesA Linear Temporal Increase in Thrombin Activity and Loss of Its Receptor in Mouse Brain following Ischemic Stroke.Antiplatelet therapy: new pharmacological agents and changing paradigms.Emerging antithrombotic drugs for acute coronary syndrome.Investigational anticoagulants for hematological conditions: a new generation of therapies.Lessons learned from negative clinical trials evaluating antithrombotic therapy for ischemic heart disease.Efficacy versus safety: the dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease.Vorapaxar: first global approval.Novel antiplatelet agents in acute coronary syndrome.Vorapaxar in atherosclerotic disease management.Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.Vorapaxar: a review of its use in the long-term secondary prevention of atherothrombotic events.Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness.Antiplatelet therapy in acute coronary syndromes.Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development.Review of vorapaxar for the prevention of atherothrombotic events.Vorapaxar in the secondary prevention of atherothrombosis.Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease.Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.Medical Therapy in Peripheral Artery Disease and Critical Limb Ischemia.Contemporary evaluation and management of lower extremity peripheral artery disease.Vorapaxar monotherapy for secondary stroke prevention: A call for randomized trial.Antithrombotic therapy for patients with STEMI undergoing primary PCI.Vorapaxar for secondary stroke prevention: perspectives and obstacles.Thrombin-induced reactive oxygen species generation in platelets: A novel role for protease-activated receptor 4 and GPIbα.Bleeding in continuous flow left ventricular assist device recipients: an acquired vasculopathy?Medical Treatment of Intracranial Atherosclerosis: An Update.Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications.Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIbIIIa Activation in Human Platelets.Targeting Platelet G Protein-Coupled Receptors for Antithrombotic Therapy
P2860
Q26748682-E6A02C1B-3484-4662-988C-1F3132A40951Q26801144-8935D262-FDA3-459B-B799-7F33896DA0F4Q27016071-30AE8474-4706-4919-B5E7-6676AA83EEE0Q30238719-99D2F341-B5C2-4C17-A4E6-68C3CBCE8052Q33580620-506B0A5C-6D5D-424F-A869-E0A55FCF32C0Q35353980-1F925935-41D9-4B25-A7D8-4AAF393AD502Q37742837-0AAC538E-49B2-4577-A266-955571B9E631Q38117743-8B5FA461-53DE-4228-89D6-1D733761875EQ38121144-DBF89A89-6D9D-4744-BDD2-91E640458764Q38123237-2E329D57-9B56-4B0E-9A07-23045FECEBD8Q38182003-D7AD5498-37E5-44F6-ADC0-4A95851606A8Q38213705-8E005C7C-8A2A-4724-96F5-92DF80FB8DE1Q38223033-710E75E8-CF44-432D-A5E1-9C39D43B205EQ38257119-5922F46C-0360-4DB4-9E99-FE6FD9211671Q38355060-C845ABA2-44AF-49E3-A79F-E1AF7EB8E11DQ38402334-97653680-A788-41C1-B1A1-AE90026D6987Q38431157-EEFDDA66-A0A8-4EE6-A930-C5DC6C40C3F9Q38566809-0C082068-4A92-40C6-995A-9786820CF89AQ38570608-771F26AA-12B8-43CD-96F7-AF5292F99329Q38592772-38149964-62A4-46D4-A40B-1BDFA5C5182EQ38610947-A4850CA5-EC8D-4A53-8201-366BE633D6A5Q38630968-C28C03EF-30AA-4B93-9679-9920F7D73D43Q38773641-C28104F9-D8A4-42F1-9142-576BCBBE6E2BQ38828773-327DBAC5-66A5-4C9C-B393-03CD256A5ED8Q38834990-F1E39493-A1F3-4604-AE10-3315BFA81DB2Q38850458-EC147247-494E-46A0-922E-8642493924ADQ38910343-244DDB75-5B5B-486B-AC36-42BAF100E7A9Q39147735-291751A6-1D38-4B0A-915E-EFFD4AD14C71Q40324010-316611E6-7F72-4B19-87D5-542129F87579Q42127781-857627D5-2C58-4E7D-8936-A86F33C9B37BQ42369262-286AE2E7-55B4-4D11-B63A-1DA59AEA2F71Q42380289-63F731C4-F1F9-4E46-B44E-F0EC1247AED4Q43226646-731A4E74-1E67-4B87-B6A2-DEB87C6AD6F6Q47142348-DE9787B6-D096-4C78-BBC5-D8A390DBC0D2Q58291538-ECBA36F6-6E88-4826-B977-306471912D08
P2860
Efficacy and safety of vorapaxar in patients with prior ischemic stroke.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Efficacy and safety of vorapaxar in patients with prior ischemic stroke.
@en
type
label
Efficacy and safety of vorapaxar in patients with prior ischemic stroke.
@en
prefLabel
Efficacy and safety of vorapaxar in patients with prior ischemic stroke.
@en
P2093
P1433
P1476
Efficacy and safety of vorapaxar in patients with prior ischemic stroke.
@en
P2093
Benjamin M Scirica
David A Morrow
Jay P Mohr
Marc P Bonaca
Mark J Alberts
Sabina A Murphy
Sebastian F Ameriso
Shinya Goto
Thrombin Receptor Antagonist i ...... ng Committee and Investigators
P304
P356
10.1161/STROKEAHA.111.000433
P407
P577
2013-02-08T00:00:00Z